Author(s): Said G, Grippon S, Kirkpatrick P
Abstract Share this page
Abstract In November 2011, tafamidis (Vyndaqel; Pfizer), a small molecule that inhibits the dissociation of transthyretin tetramers, was granted marketing authorization by the European Commission for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurological impairment.
This article was published in Nat Rev Drug Discov
and referenced in Journal of Gerontology & Geriatric Research